#Israel #Cancer Immunotherapy #Holon #AI Powered #Compugen Ltd

Compugen's Upcoming Investor Conferences Participation

Compugen Ltd., a front-runner in clinical-stage cancer immunotherapy, recently announced its participation in two key investor conferences aimed at showcasing its innovative approaches in the pharmaceutical landscape. With a dynamic selection of programs focusing on AI-driven drug target discovery, Compugen aims to bolster engagement with investors and stakeholders in the healthcare sector.

Conference Details

1. Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Date: February 26, 2026
- Location: Virtual
- Format: Fireside chat and one-on-one meetings
- Fireside Chat Time: 2 PM ET

2. Leerink Partners 2026 Global Healthcare Conference
- Date: March 9, 2026
- Location: Miami, Florida, USA
- Format: Fireside chat and one-on-one meetings
- Fireside Chat Time: 8:40 AM ET

Both events will feature live webcasts of the fireside chats, which can be accessed through the Investor Relations section of Compugen's website at www.cgen.com. For those who miss the live events, replay options will be made available shortly after they conclude.

About Compugen

Established as a pioneer in the field of cancer treatment, Compugen specializes in innovative therapeutic discovery and development. The company leverages a proprietary AI/ML-based computational discovery platform known as Unigen™. This cutting-edge technology empowers Compugen to pinpoint novel drug targets and explore biological pathways specifically tailored for the development of advanced cancer immunotherapies.

Highlighting their distinct capabilities, Compugen currently has two prominent clinical programs targeting TIGIT:

• - COM902: A promising, fully owned anti-TIGIT antibody that has advanced into Phase 1 development, expected to redefine standards in immunotherapy.
• - Rilvegostomig: An Fc-reduced PD-1/TIGIT bispecific antibody currently in Phase 3 development through a licensing agreement with AstraZeneca, illustrating their strategic collaborations in the field.

In addition to these, Compugen is advancing alternative initiatives such as COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody currently undergoing Phase 1 trials, and GS-0321, an innovative high-affinity anti-IL-18 binding protein antibody licensed to Gilead, showcasing a commitment to diversifying their therapeutic portfolio.

Looking Towards the Future

Compugen's strategic approach not only aims to refine existing cancer therapies but also opens new avenues for immuno-oncology research programs that target uncharted mechanisms for reactivating the immune response against malignancies. As the company prepares for these two significant investor gatherings, it reaffirms its commitment to transparency, shared knowledge, and industry innovation.

For stakeholders interested in the biotech and pharmaceutical sphere, these conferences present a unique opportunity to gain insights into the future of cancer treatment and the role of AI in advancing therapeutic discoveries. Compugen's leadership looks forward to these discussions, which appear to be lining up for an exciting year in the healthcare landscape.

Stay tuned for further updates as the company unveils more about its path forward and the groundbreaking work being done in immunotherapy. With compelling data and innovative plans on the horizon, Compugen is positioned as a significant player in revolutionizing cancer care.